Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099315 | 0.87 | SIGMAR1 (0.44) | SIGMAR1TMEM97CHRNB2CHRNA4 | |
| SCHEMBL18099217 | 0.87 | SIGMAR1 (0.44) | SIGMAR1TMEM97CHRNB2CHRNA4 | |
| SCHEMBL16408549 | 0.78 | SIGMAR1 (0.68) | SIGMAR1TMEM97 | |
| SCHEMBL16408589 | 0.75 | SIGMAR1 (0.51) | SIGMAR1TMEM97CHRNB2CHRNA4DRD2 | |
| SCHEMBL16408629 | 0.73 | SIGMAR1 (0.80) | SIGMAR1TMEM97DRD2 | |
| SCHEMBL21499181 | 0.73 | SIGMAR1 (0.80) | SIGMAR1TMEM97DRD2 | |
| SCHEMBL16408534 | 0.73 | SIGMAR1 (0.80) | SIGMAR1TMEM97DRD2 | |
| SCHEMBL18099330 | 0.70 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL16408661 | 0.70 | SIGMAR1 (0.69) | SIGMAR1TMEM97 | |
| SCHEMBL16397474 | 0.70 | SIGMAR1 (0.69) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885CHRNB2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.